benzyl (2-chloroethyl)methylcarbamate | 68767-11-3

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: benzyl (2-chloroethyl)methylcarbamate
• 英文别名: (2-chloro-ethyl)-methyl-carbamic acid benzyl ester；2-(N-benzyloxycarbonyl-N-methylamino)ethyl chloride；benzyl N-(2-chloroethyl)-N-methylcarbamate
• CAS: 68767-11-3
• 化学式: C₁₁H₁₄ClNO₂
• 分子量: 227.691
• InChiKey: SHHZBAVUQMNXKO-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.8
• 重原子数：
  15
• 可旋转键数：
  5
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.36
• 拓扑面积：
  29.5
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  benzyl (2-chloroethyl)methylcarbamate 在 吡啶 、 sodium hydride 作用下， 以 二甲基亚砜 为溶剂， 反应 26.0h， 生成 3-(acetyloxy)-5-<2-ethyl>-2-<4-(benzyloxy)phenyl>-2,3-dihydro-1,5-benzothiazepin-4(5H)-one
  参考文献：
  名称：

  Synthesis, characterization, and Ca2+ antagonistic activity of diltiazem metabolites

  摘要：

  Diltiazem is a calcium antagonist widely used in the treatment of angina and hypertension. The contributions of metabolites of diltiazem to the vasorelaxant effects of diltiazem were investigated. The synthesis and spectroscopic characterization of eight major cis-diltiazem metabolites are described. Three of the compounds-N, O-didemethylated metabolite (21), O-demethylated metabolite (22), and diltiazem N-oxide (27)-have been recently reported and have not previously been synthesized. The identities of all eight synthetic metabolites have been verified with samples obtained from human urine using combined LC-MS/MS. The Ca2+ antagonistic activities of diltiazem and its metabolites (except 27) were studied on hamster arota preparations depolarized with KCL The order of potencies (IC50 +/- SE, mu-M) is as follows: diltiazem (0.98 +/- 0.47) > 17 (2.46 +/- 0.38) greater-than-or-equal-to 23 (3.27 +/- 1.02) > 26 (20.2 +/- 10.5) > 22 (40.4 +/- 15.4) greater-than-or-equal-to 25 (45.5 +/- 18.1) > 21 (112.2 +/- 33.2) greater-than-or-equal-to 24 (126.7 +/- 24.2). Structure-activity relationships are also discussed.

  DOI：

  10.1021/jm00095a022
• 作为产物：
  描述：

  2-氯-N-甲基乙胺盐酸盐 、 氯甲酸苄酯 在 sodium hydroxide 作用下， 反应 0.5h， 以100%的产率得到benzyl (2-chloroethyl)methylcarbamate
  参考文献：
  名称：

  Synthesis, characterization, and Ca2+ antagonistic activity of diltiazem metabolites

  摘要：

  Diltiazem is a calcium antagonist widely used in the treatment of angina and hypertension. The contributions of metabolites of diltiazem to the vasorelaxant effects of diltiazem were investigated. The synthesis and spectroscopic characterization of eight major cis-diltiazem metabolites are described. Three of the compounds-N, O-didemethylated metabolite (21), O-demethylated metabolite (22), and diltiazem N-oxide (27)-have been recently reported and have not previously been synthesized. The identities of all eight synthetic metabolites have been verified with samples obtained from human urine using combined LC-MS/MS. The Ca2+ antagonistic activities of diltiazem and its metabolites (except 27) were studied on hamster arota preparations depolarized with KCL The order of potencies (IC50 +/- SE, mu-M) is as follows: diltiazem (0.98 +/- 0.47) > 17 (2.46 +/- 0.38) greater-than-or-equal-to 23 (3.27 +/- 1.02) > 26 (20.2 +/- 10.5) > 22 (40.4 +/- 15.4) greater-than-or-equal-to 25 (45.5 +/- 18.1) > 21 (112.2 +/- 33.2) greater-than-or-equal-to 24 (126.7 +/- 24.2). Structure-activity relationships are also discussed.

  DOI：

  10.1021/jm00095a022

文献信息

• 1,5-benzothiazepine derivatives and processes for preparing the same
  申请人：Tanabe Seiyaku Co., Ltd.

  公开号：US04585768A1

  公开（公告）日：1986-04-29

  Novel 1,5-benzothiazepine derivatives of the formula: ##STR1## wherein R.sup.1 is hydrogen or lower alkyl, R.sup.2 is hydrogen, lower alkanoyl or benzyl, R.sup.3 is hydrogen or lower alkyl and either one of R.sup.4 and R.sup.5 is hydrogen and the other is chlorine, or a pharmaceutically acceptable acid addition salt thereof are disclosed. Said derivative (I) and its salt have a potent platelet aggregation-inhibiting activity.

  公开了一种通式为##STR1##的新型1,5-苯并硫氮杂草衍生物，其中R1是氢或低级烷基，R2是氢、低级烷酰基或苄基，R3是氢或低级烷基，R4和R5中任一为氢，另一为氯，或其药学上可接受的酸加成盐。该衍生物(I)及其盐具有强大的血小板聚集抑制活性。
• Indole derivatives
  申请人：Kyowa Hakko Kogyo Co., Ltd.

  公开号：US05891902A1

  公开（公告）日：1999-04-06

  The present invention relates to indole derivatives represented by formula (I): ##STR1## wherein R.sup.1 and R.sup.2 independently represent hydrogen, lower alkyl, hydroxy, lower alkoxy, halogen, --O--(CH.sub.2).sub.n --OR.sup.5, or ##STR2## R.sup.3 represents hydrogen, lower alkyl, or ##STR3## R.sup.4 represents hydroxy, lower alkoxy, substituted or unsubstituted aryloxy, or --NR.sup.10 R.sup.11, and X represents CO or SO.sub.2, with the proviso that when R.sup.3 is hydrogen or lower alkyl, and X is CO, R.sup.4 is --NR.sup.10 R.sup.11, or pharmaceutically acceptable salts thereof.

  本发明涉及由式(I)表示的吲哚衍生物：其中R.sup.1和R.sup.2独立地表示氢、较低的烷基、羟基、较低的烷氧基、卤素、--O--(CH.sub.2).sub.n --OR.sup.5，或R.sup.3表示氢、较低的烷基，或R.sup.4表示羟基、较低的烷氧基、取代或未取代的芳基氧基，或--NR.sup.10 R.sup.11，X表示CO或SO.sub.2，但当R.sup.3为氢或较低的烷基，且X为CO时，R.sup.4为--NR.sup.10 R.sup.11，或其药学上可接受的盐。
• Synthesis of the metabolites and related compounds of Diltiazem.
  作者：MICHIHIKO MIYAZAKI、TAKEO IWAKUMA、TADASU TANAKA

  DOI：10.1248/cpb.26.2889

  日期：——

  Major metabolites of the antianginal drug, Diltiazem, 3 (S)-(acetyloxy)-5-[2-(dimethylamino)ethyl]-2, 3-dihydro-2(S)-(4-methoxyphenyl)-1, 5-benzothiazepin-4(5H)-one, have been synthesized. In connection with these metabolites, several S- and N-oxides were prepared.

  抗心绞痛药物地尔硫卓的主要代谢物 3 (S)-(乙酰氧基)-5-[2-(二甲基氨基)乙基]-2, 3-二氢-2(S)-(4-甲氧基苯基)-1, 5-苯并硫氮杂卓-4(5H)-酮已被合成。与这些代谢物相关，还制备了几种 S-和 N-氧化物。
• 1,5-benzothiazepine derivative
  申请人：Tanabe Seiyaku Co., Ltd.

  公开号：US04594342A1

  公开（公告）日：1986-06-10

  Novel 1,5-benzothiazepine derivatives of the formula: ##STR1## wherein R.sup.1 and R.sup.4 are: (a) R.sup.1 is lower alkyl or lower alkoxy, and R.sup.4 is lower alkyl, lower alkoxy, fluorine, benzyloxy, hydroxy or lower alkylthio, or (b) R.sup.1 is lower alkyl, and R.sup.4 is hydrogen, or (c) R.sup.1 is hydroxy, and R.sup.4 is lower alkyl, fluorine, hydroxy or lower alkylthio; R.sup.2 is hydrogen, lower alkanoyl or benzoyl; and R.sup.3 is lower alkyl; and a pharmaceutically acceptable acid addition salt thereof are disclosed. Said derivative (I) and its salt have a potent platelet aggregation-inhibiting activity.

  公开了式子为：##STR1##的1,5-苯并噻吩衍生物，其中R.sup.1和R.sup.4为：(a) R.sup.1为低烷基或低烷氧基，R.sup.4为低烷基，低烷氧基，氟，苄氧基，羟基或低烷硫基，或(b) R.sup.1为低烷基，R.sup.4为氢，或(c) R.sup.1为羟基，R.sup.4为低烷基，氟，羟基或低烷硫基；R.sup.2为氢，低烷酰基或苯甲酰基；R.sup.3为低烷基；以及其药学上可接受的酸加合物盐。该衍生物(I)及其盐具有强大的血小板聚集抑制活性。
• Compounds and their uses 708
  申请人：AstraZeneca AB

  公开号：US08163905B2

  公开（公告）日：2012-04-24

  The present invention relates to pyrazinone derivatives of formula (I): wherein R1, R2, R3, R4, R5, R6 and R7 are as herein defined; processes for their preparation, pharmaceutical compositions containing them and their use in therapy.

  本发明涉及式(I)的吡嗪酮衍生物，其中R1，R2，R3，R4，R5，R6和R7如本文所定义；其制备过程，包含它们的药物组合物以及它们在治疗中的使用。